Latest News

Dato-DXd May Be Next SOC in First-Line TNBC
Dato-DXd May Be Next SOC in First-Line TNBC

October 20th 2025

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.
Data Show Growing Trend in Insurance/Racial OS Disparities in Breast Cancer

October 20th 2025

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.
PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

October 19th 2025

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.
Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer

October 19th 2025

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.
Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer

October 19th 2025

Video Series
Video Interviews
Podcasts
Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Latest CME Events & Activities

More News